EUVIMEDEUVIMED entdecken
Crossref

Limited value of genetic profiling in guiding radioiodine therapy for metastatic differentiated thyroid cancer

Ziyan He, Congcong Wang, Chang Liu, Ke Zhang, Junyao Wang, Xufu Wang, Yifan Zhang iD, Libo Chen iD

Endocrine-Related Cancer · 2025

DOI: 10.1530/erc-24-0298 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrine-Related Cancer, 2025. Verfasst von Ziyan He und 7 weiteren Autor:innen. Hauptthemen laut MEDLINE: Iodine Radioisotopes, Thyroid Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Assessing the 131I-avidity of metastatic differentiated thyroid cancer (mDTC) is pivotal to characterizing the nature of disease and optimizing the therapeutic strategy. In this prospective study, the predictive value of genetic profiling of 18 selected thyroid cancer-relevant genes for 131I-avidity and the response to radioiodine therapy (RT) was studied in comparison with those of diagnostic 131I scan. During univariate analysis, BRAF status (odds ratio, (OR) = 12.47, 95% confidence interval (CI): 5.03–30.89, P < 0.001) and TNM-M stage (P = 0.029) were found to be associated with 131I-avidity, but multivariate analysis identified BRAFV600E as the sole independent factor associated with the non-131I-avidity (OR = 12.98, 95% CI: 3.77–44.73, P < 0.001). The predictive values of BRAF wild-type for 131I-avidity and BRAFV600E for non-131I-avidity were 84.6 and 69.4%, respectively, both lower than those of diagnostic 131I scan (positive predictive value of 100%, P = 0.031; negative predictive value of 81.1%, P = 0.219). The predictive value of BRAFV600E for non-131I-avidity was not significantly improved when combined with TERT promoter mutation (76.9 vs 69.4%, P = 0.736). Moreover, the predictive value of BRAFV600E for biochemical non-response was 70.8% (17/24), while no correlation was found between BRAF status and structural response. In contrast, a negative diagnostic 131I scan was significantly associated with both biochemical and structural non-responses, with predictive values of 81 and 100%, respectively. The current study demonstrated that genetic profiling is of limited value in guiding RT for mDTC, while a diagnostic 131I scan proved superior in this respect.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Iodine RadioisotopesThyroid NeoplasmsHumansFemaleMaleMiddle AgedAdultProto-Oncogene Proteins B-rafAgedProspective StudiesGenetic ProfileTelomeraseMutationYoung Adult

Stichwörter der Autor:innen

BRAF V600Ediagnostic 131I scandifferentiated thyroid cancergenetic profilingradioiodine therapy

Substanzen

Iodine RadioisotopesProto-Oncogene Proteins B-rafBRAF protein, humanIodine-131Telomerase

Autor:innen und Institutionen

ORCID-Profile: Yifan Zhang, Libo Chen

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

He, Z., Wang, C., Liu, C., Zhang, K., Wang, J., Wang, X., Zhang, Y., & Chen, L. (2025). Limited value of genetic profiling in guiding radioiodine therapy for metastatic differentiated thyroid cancer. Endocrine-Related Cancer. https://doi.org/10.1530/erc-24-0298

Vancouver

He Z, Wang C, Liu C, Zhang K, Wang J, Wang X, et al. Limited value of genetic profiling in guiding radioiodine therapy for metastatic differentiated thyroid cancer. Endocrine-Related Cancer. 2025. doi:10.1530/erc-24-0298

BibTeX
@article{He2025,
  author = {He, Ziyan and Wang, Congcong and Liu, Chang and Zhang, Ke and Wang, Junyao and Wang, Xufu and Zhang, Yifan and Chen, Libo},
  title = {Limited value of genetic profiling in guiding radioiodine therapy for metastatic differentiated thyroid cancer},
  journal = {Endocrine-Related Cancer},
  year = {2025},
  doi = {10.1530/erc-24-0298}
}
Kostenlos starten →